an experimental experience

https://www.onclive.com/view/trastuzumab-deruxtecan-has-clinically-meaningful-activity-in-solid-tumors-harboring-her2-mutations

+ 85 more

10/22/23 at 6:07pm

Organization

OncLive

Author

Ryan Scott

34 words

Comments

Fam-trastuzumab deruxtecan-nxki elicited responses that proved to be durable in patients with a range of solid tumors harboring HER2 mutations.

Cancer Enhertu

You are the first to view

Create an account or login to join the discussion